A controlled, randomized, delayed-start study of rasagiline in early parkinson disease

Archives of Neurology

Volumn 61, Issue 4, 2004, Pages 561-566

  Shoulson, ^a   Fahn, ^a   Kieburtz, ^a   Stern, ^a   Siderowf, ^a   Blindauer, ^a   Goren, ^a   Levy, ^a   Plumb, ^a   Eyal, ^a   Lew, ^a   Hurtig, ^a   Lloyd, ^a   Hauser, ^a   Golbe, ^a   Wojcieszek, ^a   Feigin, ^a   Ondo, ^a   Calabrese, ^a   Atchison, ^a   Marshall, ^a   Miyasaki, ^a   Mendis, T ^a   Mendis, N ^a   Hubble, ^a   Pahwa, ^a   Molho, ^a   Shulman, ^a   Rajput, ^a   Stacy, ^a   Bertoni, ^a   Tuite, ^a   Shannon, K ^a   Tanner, ^a   Marek, ^a   Aminoff, ^a   Dowling, ^a   Kang, ^a   Sethi, ^a   Martin, ^a   Adler, ^a   Gordon, ^a   Feldman, ^a   Schwid, ^a   Salzman, ^a   Day, ^a   Shinaman, ^a   Brocht, ^a,a   Gauger, ^a   Belden, ^a   Klimek, ^a   Shannon, B ^a   Hunter, ^a   Berry, ^a   Gardiner, ^a   Del Rizzo, ^a   Gray, ^a   Betcher, ^a   Brown, ^a   Ewanishin, ^a   Williamson, ^a   Peterson, ^a   Ebbitt, ^a   Jaglin, ^a   Kawai, ^a   Stavris, ^a   DiMinno, ^a   Richman, ^a   King, ^a   McInnes, ^a   DeAngelis, ^a   Winnick, ^a   Thomas, ^a   Evans, ^a   Lind, ^a   Roberge, ^a   Conn, ^a   Connolly, ^a   Daigneault, ^a   Oliva, ^a   Josephson, ^a   Chadwick, ^a   Lang, ^a   White, ^a   Nutt, ^a   Cox, ^a   Eberly, ^a,a   Bausch, ^a   Irvine, ^a   Loyd, ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RASAGILINE; ANTIPARKINSON AGENT; INDAN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CANADA; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; UNITED STATES; VASCULAR DISEASE; CLASSIFICATION; COHORT ANALYSIS; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 2342655732     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.61.4.561     Document Type: Article

References (17)

1. Finberg JP, Tenne M, Youdim MB. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981; 73:65-74.
2. Heikkila RE, Duvoisin RC, Finberg JP, Youdim MBH. Prevention of MPTPinduced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol. 1985;116:313-317.
3. Akao Y, Maruyama W, Yi H, et al. An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326:105-108.
4. Maruyama W, Akao Y, Carrillo MC, et al. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002;24:675-682.
5. Marek KL, Friedman J, Hauser R, et al. Phase II evaluation of rasagiline mesylate (TVP-1012), a novel anti-parkinsonian drug, in parkinsonian patients not using levodopa/carbidopa [abstract]. Mov Disord. 1997;12:838.
6. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
7. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord. 1997;11(suppl 5):S10-S21; discussion, S37-S39.
8. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
9. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson’s Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-164.
10. Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208:1168-1170.
11. Abu-Raya S, Blaugrund E, Trembovler V, et al. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygenglucose deprivation. J Neurosci Res. 1999;58:456-463.
12. Maruyama W, Yamamoto T, Kitani K, et al. Mechanism underlying antiapoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev. 2000;116:181-191.
13. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366:127-135.
14. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem. 2002;82:913-923.
15. Youdin MBH, Wadia A, Tatton NA, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci. 2001;939:450-458.
16. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176-183.
17. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson’s disease. Ann Neurol. 1996;40:99-107.